Vaccitech PLC
Change company Symbol lookup
Select an option...
VACC Vaccitech PLC
PNR Pentair PLC
AAL American Airlines Group Inc
AMD Advanced Micro Devices Inc
IDAI T Stamp Inc
VZ Verizon Communications Inc
CETX Cemtrex Inc
RNXT RenovoRx Inc
BNTX BioNTech SE
ARTW Art's Way Manufacturing Co Inc
Go

Health Care : Biotechnology |
Based in United Kingdom
Company profile

Vaccitech plc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The Company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The Company has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$2.25
Day's Change
-0.2236 (-9.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.31
Day's Low
2.16
Volume
(Heavy Day)

Today's volume of 168,637 shares is on pace to be much greater than VACC's 10-day average volume of 164,005 shares.

168,637

SkinMedica(R) Launches Even & Correct

8:00 am ET January 17, 2023 (PR Newswire) Print

The Results Are Clear - A Scientifically Proven Path to Targeting the Appearance of Hyperpigmentation and Improving Skin Tone and Texture

Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of the long-awaited SkinMedica(R) Even & Correct Collection. Clinically proven and formulated to deliver targeted results, these three products work separately and together to even skin tone and reduce the appearance of hyperpigmentation and dark spots on the face: Advanced Brightening Treatment, Dark Spot Cream, and Brightening Treatment Pads.

https://mma.prnewswire.com/media/1983474/SkinMedica_Even__Correct_Collection.jpg

"Hyperpigmentation is the second-highest professional-grade skincare concern seen in-office1 with demand for effective treatment continuing to rise," said Carrie Strom, President, Global Allergan Aesthetics and Senior Vice President, AbbVie. "With a formulation backed by science, our R&D team has developed an innovative collection to meet patients where they are in their hyperpigmentation journey. SkinMedica(R) continues to be a category leader innovating for all patient skin types."

"Hyperpigmentation is a complex, emotional condition that is often misunderstood and can be difficult to treat as diverse skin types and tones present with hyperpigmentation and respond to treatment in different ways," said Dr. Corey L. Hartman, Board-certified dermatologist and Founder of Skin Wellness Dermatology in Birmingham, AL. "My approach to hyperpigmentation treatment for my patients are nuanced and multimodal to treat existing discoloration and prevent future spots by targeting the root cause. The collection is a customizable and comprehensive approach that can be used together or individually to help target a broad spectrum of unwanted hyperpigmentation conditions, including melasma and post-inflammatory hyperpigmentation (PIH) and effectively targets six critical pathways associated with melanogenesis."

The SkinMedica(R) Even & Correct products are hydroquinone-free, well tolerated, and effective on all skin types and for multiple ethnicities. Results can be amplified in-offices by receiving a DiamondGlow(R) treatment with Even & Correct Advanced Brightening Pro-Infusion Serum.

"Patent-pending and exclusive to SkinMedica(R), the LTN Complex™ used in the Even & Correct collection features Ultra-Concentrated Lotus Sprout Extract enriched in phytochemicals through a specialized extraction process to harness the most powerful properties that address skin discoloration, Tranexamic Acid to reduce the appearance of dark spots and Niacinamide to reduce the appearance of skin discoloration and fine lines," said Dr. Prithwiraj Maitra, Executive Director, Global Skincare R&D, Allergan Aesthetics. "In clinical studies, individuals saw visibly brighter, more even skin tone in as little as one week.2"

-- SkinMedica(R) Even & Correct Advanced Brightening Treatment: A powerful daily serum to help target and prevent visible discoloration.

-- 83% of patients agreed that "the serum improved the evenness of my skin tone," at week 8 (n=108)

-- 80% agreed "it makes my skin look less dull," at week 8 (n=108)

-- 84% agreed "it improved the overall appearance of my skin," at week 12 (n=110)

-- SkinMedica(R) Even & Correct Dark Spot Cream: A heavy-duty, targeted, fast-acting spot treatment booster that minimizes the look of dark spots.

-- 75% of patients agreed that "it improved the appearance of uneven skin tone and discolorations," at week 8 (n=41)

-- 74% agreed "it visibly reduced the size of dark spots," at week 8 (n=41)

-- 78% agreed "it visibly reduced the size and intensity of my uneven pigment," at week 8 (n=41)

-- 78% agreed "it reduced the appearance of my sunspots," at week 12 (n=41)

-- SkinMedica(R) Even & Correct Brightening Treatment Pads: Alcohol-free brightening pads exfoliate and help reduce the appearance of dullness and uneven tone and texture.

SkinMedica(R) Even & Correct Advanced Brightening Treatment ($178 MSRP), SkinMedica(R) Even & Correct Dark Spot Cream ($88 MSRP), and SkinMedica(R) Even & Correct Brightening Treatment Pads ($60 MSRP) are available for purchase at SkinMedica.com, and through a network of licensed physicians and medically supervised spas. To experience the SkinMedica(R) Even & Correct Advanced Brightening Pro-Infusion Serum for DiamondGlow(R), you can find a provider near you by clicking here. For more information follow @SkinMedica on Instagram or click here.

About Allergan AestheticsAt Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skincare, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visitwww.AllerganAesthetics.com.

About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us atwww.abbvie.com. Follow@abbvieonTwitter,Facebook,Instagram,YouTubeandLinkedIn.

SkinMedica(R) IMPORTANT INFORMATIONCAUTION: Do not use Even & Correct Dark Spot Cream if you are pregnant, lactating, or planning to become pregnant.

Sunburn alert: Even & Correct Brightening Treatment Pads and Even & Correct Dark Spot Cream contain an alpha-hydroxy acid (AHA) that may increase your skin's sensitivity to sunburn. Use a sunscreen and limit sun exposure while using these products and for a week following discontinuation.

Use a sunscreen with an SPF of 30 or higher during any sun exposure when using Even & Correct Advanced Brightening Treatment.

Most SkinMedica(R) products are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica(R) products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA.

DiamondGlow(R)UsesThe DiamondGlow(R) device is a general dermabrasion device that gently removes the top layer of skin and delivers topical cosmetic serums onto the skin.

DiamondGlow(R) Important Safety InformationThe DiamondGlow(R) treatment is not for everyone. You should not have a DiamondGlow(R) treatment if you have compromised skin quality. Tell your provider if you are pregnant or lactating, or if you have any medical conditions, including allergies, and if you are using topical medications on the area to be treated.

Typical side effects include a scratchy, stinging sensation during the treatment and temporary tightness, redness or slight swelling after the treatment. Rare serious side effects may also occur and include severe skin irritation and allergic reactions.

SkinMedica(R)Pro-Infusion Serums DisclaimerSkinMedica(R)Pro-Infusion Serums are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These products are not intended to be drugs that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA.

Please talk to your provider for additional information.

For more information, please talk to your provider or visit SkinMedica.com and DiamondGlow.com. To report an adverse reaction, please call Allergan at 1-800-433-8871.

References:

-- 2021 Kline Professional Skin Care Executive Study.

-- Data on file at SkinMedica(R).

https://mma.prnewswire.com/media/1983475/SkinMedica_Logo.jpg

https://c212.net/c/img/favicon.png?sn=CG86620&sd=2023-01-17

View original content to download multimedia:https://www.prnewswire.com/news-releases/skinmedica-launches-even--correct-301721744.html

SOURCE AbbVie

https://rt.newswire.ca/rt.gif?NewsItemId=CG86620&Transmission_Id=202301170800PR_NEWS_USPR_____CG86620&DateId=20230117

comtex tracking

COMTEX_422814870/1005/2023-01-17T08:00:16

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.